Boston Scientific will pay $189 million to settle a multi-state lawsuit over the marketing of the company’s surgical mesh devices.
Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.
BioSpace reviews whose wallets got thicker in the biopharma industry, from largest to smallest, during the Nov. 11-17 period
Shares of Inovio Pharmaceuticals plunged in trading after the company reported the U.S. Food and Drug Administration placed a partial clinical hold on the planned Phase II/III study of the Covid-19 vaccine candidate INO-4800.
Soliton Inc. selected Greater Than One Group as the medical device company’s integrated marketing agency.
Eli Lilly and Company announced positive results from CENTURION, the company’s Phase III study looking into Reyvow (lasmiditan) for migraine attacks.
The U.S. Food and Drug Administration approved a new indication for GlaxoSmithKline plc and Innoviva Inc.’s Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to the product’s current license for use in patients with chronic obstructive pulmonary disease (COPD).
EVERSANA™ expands pharmaceutical training and digital engagement capabilities with acquisition of Alkemy Partners CHICAGO, Sept. 9, 2020 /PRNewswire/ — EVERSANA™, the leading provider of commercial services to the life science industry, […]
The U.S. Food and Drug Administration approved FoundationOne Liquid CDx, a new pan-tumor liquid biopsy test that is indicated for use as a companion diagnostic for four FDA-approved precision therapies.
German drugs and pesticides group Bayer will pay around $1.6 billion to settle the majority of U.S. claims involving the Essure birth-control device.